Neurenati Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$2.17M
- Investors
-
3
Neurenati Therapeutics General Information
Description
Developer of novel regenerative therapies intended for the treatment of Hirschsprung disease. The company focuses on developing innovative therapy via growth factor to treat newborns with Hirschsprung disease, a life-threatening gastrointestinal birth defect, providing doctors with a non-surgical alternative to treat rare GI diseases in newborns.
Contact Information
Website
www.neurenati.comCorporate Office
- 630 René-Lévesque Boulevard West
- 20th Floor
- Montreal, Quebec H3B 1S6
- Canada
Corporate Office
- 630 René-Lévesque Boulevard West
- 20th Floor
- Montreal, Quebec H3B 1S6
- Canada
Neurenati Therapeutics Timeline
Neurenati Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Seed Round | 25-Sep-2025 | $2.17M | Completed | Pre-Clinical Trials | ||
| 2. Seed Round | 18-Apr-2024 | Completed | Pre-Clinical Trials | |||
| 1. Seed Round | 29-Feb-2024 | $889K | $889K | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Neurenati Therapeutics Comparisons
Industry
Financing
Details
Neurenati Therapeutics Competitors (1)
One of Neurenati Therapeutics’s competitors is Harvard University, a Corporation company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Harvard University | Corporation | Cambridge, MA |
Neurenati Therapeutics Signals
Neurenati Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| Investissement Quebec | PE/Buyout | Minority | ||
| Genson Capital | Venture Capital | Minority |
Neurenati Therapeutics FAQs
-
When was Neurenati Therapeutics founded?
Neurenati Therapeutics was founded in 2020.
-
Where is Neurenati Therapeutics headquartered?
Neurenati Therapeutics is headquartered in Montreal, Canada.
-
What is the size of Neurenati Therapeutics?
Neurenati Therapeutics has 5 total employees.
-
What industry is Neurenati Therapeutics in?
Neurenati Therapeutics’s primary industry is Biotechnology.
-
Is Neurenati Therapeutics a private or public company?
Neurenati Therapeutics is a Private company.
-
What is the current valuation of Neurenati Therapeutics?
The current valuation of Neurenati Therapeutics is .
-
What is Neurenati Therapeutics’s current revenue?
The current revenue for Neurenati Therapeutics is .
-
How much funding has Neurenati Therapeutics raised over time?
Neurenati Therapeutics has raised $4.31M.
-
Who are Neurenati Therapeutics’s investors?
, Investissement Quebec, and Genson Capital have invested in Neurenati Therapeutics.
-
Who are Neurenati Therapeutics’s competitors?
Harvard University is a competitor of Neurenati Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process